Mesolimbic opioid-dopamine interaction is disrupted in obesity but recovered by weight loss following bariatric surgery

Henry K. Karlsson¹, Lauri Tuominen^{1,2}, Semi Helin¹, Paulina Salminen³, Pirjo Nuutila^{1,4} and Lauri Nummenmaa^{1,5}

¹Turku PET Centre, University of Turku, Turku, Finland

²Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada

³Department of Digestive Surgery, University of Turku and Turku University Hospital, Turku, Finland

⁴Department of Endocrinology, Turku University Hospital, Turku, Finland

⁵Department of Psychology, University of Turku, Turku, Finland

Corresponding author

Henry Karlsson
Turku PET Centre
c/o Turku University Hospital
Kiinamylynkatu 4-8
FI-20520 Turku
Finland

Key words: Obesity; positron emission tomography; reward; opioid; dopamine; receptors; bariatric surgery; weight loss

Conflict of Interest

The authors declare no competing financial interests.

Author contributions

HK: Acquired and analyzed PET data, wrote the manuscript

LT: Analyzed PET data, wrote the manuscript

SH: Produced the radiotracers, wrote the manuscript

PS: Recruited the study subjects, wrote the manuscript

PN: Designed the experiments, wrote the manuscript

LN: Designed the experiments, wrote the manuscript

Acknowledgments

The study was conducted within the Finnish Centre of Excellence in Cardiovascular and Metabolic Diseases supported by the Academy of Finland (grants #251125, #121031, #304385), Sigrid Juselius Foundation, University of Turku, Turku University Hospital and Åbo Akademi University. HKK was supported by personal grants from The Finnish Diabetes Research Foundation and The National Graduate School of Clinical Investigation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors thank the staff of the Turku PET Centre for assistance in the PET imaging. Special thanks goes to research nurse Mia Koutu.

Abstract

Background: Obesity is a growing burden to health and economy worldwide. Obesity is associated with central μ -opioid receptor (MOR) downregulation, and the interaction between MOR and dopamine D₂ receptor (D₂R) system in the ventral striatum is disrupted among obese subjects. Weight loss recovers MOR function, but it remains unknown whether it also recovers aberrant opioid-dopamine interaction. Here we addressed this issue by studying subjects undergoing surgical weight loss (bariatric surgery) procedure.

Methods: We recruited 20 healthy non-obese (mean BMI 22) and 25 morbidly obese women (mean BMI 41) eligible for bariatric surgery. Brain MOR and D₂R availability was measured using positron emission tomography (PET) with [¹¹C]carfentanil and [¹¹C]raclopride, respectively. Either Roux-en-Y gastric bypass or sleeve gastrectomy was performed to obese subjects according to standard clinical treatment. 21 obese subjects participated in the postoperative PET scanning six months after bariatric surgery.

Results: In the control subjects, MOR and D₂R availabilities were associated in the ventral striatum ($r = .62$) and dorsal caudate ($r = .61$). Preoperatively, the obese subjects had disrupted association in the ventral striatum ($r = .12$) but unaltered association in dorsal caudate ($r = .43$). The association between MOR and D₂R availabilities in the ventral striatum was recovered ($r = .62$) among obese subjects following the surgery-induced weight loss (mean total weight loss 22 %).

Conclusions: Bariatric surgery and concomitant weight loss recovers the interaction between MOR and D₂R in the ventral striatum in the morbidly obese. Consequently, the dysfunctional opioid-dopamine interaction in the ventral striatum is likely associated with an obese phenotype and may mediate excessive energy uptake. Striatal opioid-dopamine interaction provides a feasible target for pharmacological and behavioural interventions for treating obesity.

Clinical Trials Registration: SleevePET2, NCT01373892, <http://www.clinicaltrials.gov>

Introduction

The prevalence of obesity is dramatically increasing and there is urgent need for novel efficient therapies. Numerous studies point towards the role of brain in the development and maintenance of obesity (Stice and Burger, 2019; Morales and Berridge, 2020). Previous studies indicate that both opioid and dopamine systems in brain's reward circuit are dysfunctional in obesity. Endogenous opioid system has been linked to hedonic aspects of feeding in animals (Pecina and Smith, 2010; Fields and Margolis, 2015). In humans, both μ -opioid receptor (MOR) antagonists and inverse agonists have been shown to reduce eating behaviour (Nathan et al., 2012; Cambridge et al., 2013). Previously, decreased MOR availability has been observed in reward circuit among obese subjects (Burghardt et al., 2015; Karlsson et al., 2015). Thus, aberrant opioid functioning in obesity may diminish the opioid dependent rewarding effects of eating. Alterations in dopamine D₂ receptor (D₂R) expression and function in obesity has been observed in some (Volkow et al., 2008; Stice et al., 2011; Salamone and Correa, 2013; Lee et al., 2018) but not all human imaging studies (Eisenstein et al., 2013; Karlsson et al., 2015). It is possible that the relationship between D₂R availability and measures of obesity is not linear, but quadratic (Horstmann et al., 2015) or age-dependent (Dang et al., 2016). Alternatively, it is possible that the effects of obesity on D₂R are mediated via the MOR system.

Tight interaction between dopaminergic and opioidergic systems has been proposed to underlie human reward functions (Le Merrer et al., 2009), but only a few studies have actually investigated this issue. In humans, dopamine-releasing drugs such as cocaine and amphetamine lead to endogenous opioid release (Soderman and Unterwald, 2009; Colasanti et al., 2012; Mick et al., 2014). In rats, both D₂Rs and MORs are closely connected in the striatum, which can be morphologically divided into striosome/patch and matrix compartments. MORs can control the release of dopamine through inhibiting GABAergic interneurons in VTA (Spanagel et al., 1992; Kalivas, 1993; Volkow and Wise, 2005; Rada et al., 2010; Jalabert et al., 2011; Chartoff and Connery, 2014). Furthermore, VTA dopamine neurons express MOR postsynaptically, and direct

inhibition between MOR and dopamine neurons exists without GABAergic signaling (Margolis and Hjelmstad, 2014).

Cross-talk between opioidergic and dopaminergic system may underlie aberrant reward-related behaviours, such as excessive feeding. In rats, intravenous administration of MOR agonists triggers dopamine release and feeding (Yeomans and Gray, 2002), while MOR antagonists block dopamine release and reduce food consumption (Taber et al., 1998). Finally, *in vivo* PET data from humans show that there is a close interaction between MOR and D₂R receptors in the reward circuit among non-obese subjects, while this interaction is disrupted in the ventral striatum among obese subjects, potentially contributing to obesity (Tuominen et al., 2015). However, it remains unclear whether the dysfunctional MOR / D₂R interaction reflects a vulnerability endophenotype for obesity, or whether it develops as a consequence of the obese state.

Bariatric surgery is the most effective method for weight loss in obesity (Adams et al., 2017). The surgical procedure significantly lowers appetite (Bryant et al., 2020), but the actual molecular brain mechanisms behind this are still poorly understood. Bariatric surgery provides a powerful method for investigating changes in neuroreceptor systems and opioid-dopamine interaction after weight gain. Previous studies have investigated effects of bariatric surgery and following weight loss to separate receptor systems, showing mainly unaltered D₂R availability and normalized MOR availability (Dunn et al., 2010; Steele et al., 2010; de Weijer et al., 2014; Karlsson et al., 2016). Here we tested whether bariatric surgery induced weight loss could recover the dysfunctional opioid-dopamine interaction in the obese.

Materials and Methods

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethical Committee of the Hospital District of South-Western Finland (SleevePET2, NCT01373892, <http://www.clinicaltrials.gov>). All participants gave signed informed consent form prior to scans.

Subjects

We recruited 25 morbidly obese women (mean BMI 41 kg/m²) eligible for bariatric surgery. Either Roux-en-Y gastric bypass or sleeve gastrectomy was performed as their standard clinical treatment. Four subjects discontinued the study for personal reasons, and 21 participated in the postoperative scanning six months after the surgical procedure. 20 non-obese healthy women (mean BMI 22 kg/m²) formed the control group. Data for this patient cohort have been reported previously (Karlsson et al., 2015; Tuominen et al., 2015; Karlsson et al., 2016). Characteristics of the subjects are presented in the Table 1. Clinical screening of the subjects included history, physical examination, anthropometric measurements, and laboratory tests. Exclusion criteria involved opiate drug use, binge-eating disorders, neurological and severe mental disorders, substance abuse, excessive alcohol consumption (more than eight units per weeks) determined by clinical interviews, medical history, and blood tests. None of the controls smoked tobacco, but 8 obese subjects were smokers (3-15 cigarettes per day). Antidiabetic, antihypertensive, and cholesterol lowering drugs were paused prior to the study.

Table 1. Characteristics of the subjects. Data are presented as mean $\pm$ SD.

	Obese preoperative (N = 25)	Obese postoperative (N = 21)	Healthy control subjects (N = 20)
Age (y)	41.2 $\pm$ 9.2	-	42.0 $\pm$ 13.2
BMI (kg/m ²)	41.3 $\pm$ 4.1	31.9 $\pm$ 4.4	22.4 $\pm$ 2.6
Percentage of fat (%)	50.3 $\pm$ 6.7	43.2 $\pm$ 4.2	30.6 $\pm$ 6.4

Tobacco smokers / non-smokers (N)	8 / 17	5 / 16	0 / 20
Amount of alcohol use (units per week)	1.7 ± 1.8	N / A	2.9 ± 2.3
Injected activity of [¹¹ C]carfentanil (MBq)	253.2 ± 11.6	252.1 ± 15.0	251.2 ± 8.4
Injected activity of [¹¹ C]raclopride (MBq)	247.9 ± 20.8	254.5 ± 10.9	258.3 ± 15.7

Image Acquisition and Quantification of Receptor Availability

We measured D₂ receptor availability with the antagonist [¹¹C]raclopride (Farde et al., 1986) and μ-opioid receptor availability with the high-affinity agonist [¹¹C]carfentanil (Frost et al., 1985) using positron emission tomography (PET) on two separate visits. Subjects were scanned again with both radiotracers six months after bariatric surgery. Radiotracer production has been described previously (Karlsson et al., 2015). Both radioligands had high radiochemical purity (>99 %). Before scanning, a catheter was placed in the subject's left antecubital vein for tracer administration. Head was strapped to the scanner table in order to prevent head movement. Subjects fasted two hours prior to scanning. A CT scan was performed to serve as attenuation map. Clinical well-being of subjects were monitored during the scanning.

We injected both tracers as bolus in separate scans on separate days. Injected amounts of [¹¹C]carfentanil and [¹¹C]raclopride are presented in the Table 1. After injection, radioactivity in brain was measured with the GE Healthcare Discovery™ 690 PET/CT scanner (General Electric Medical Systems, Milwaukee, WI, USA) for 51 minutes, using 13-time frames. MR imaging was performed with Philips Gyroscan Intera 1.5 T CV Nova Dual scanner to exclude structural abnormalities and to provide anatomical reference images for the PET

scans. Anatomical images (1 mm³ voxel size) were acquired using a T1-weighted sequence (TR 25 ms, TE 4.6 ms, flip angle 30°, scan time 376 s).

All alignment and coregistration steps were performed using SPM8 software (www.fil.ion.ucl.ac.uk/spm/) running on Matlab R2012a (The Mathworks Inc., Sherborn, Massachusetts). To correct for head motion, dynamic PET images were first realigned frame-to-frame. The individual T1-weighted MR images were coregistered to the summation images calculated from the realigned frames. Regions of interest (ROIs) for reference regions were drawn manually on MRI images using PMOD 3.4 software (PMOD Technologies Ltd., Zurich, Switzerland). Occipital cortex was used as the reference region for [¹¹C]carfentanil and cerebellum for [¹¹C]raclopride. Receptor availability was expressed in terms of BP_{ND} , which is the ratio of specific to non-displaceable binding in brain. BP_{ND} was calculated applying basis function method for each voxel using the simplified reference tissue model (SRTM) with reference tissue time activity curves (TAC) as input data (Gunn et al., 1997).

The subject-wise parametric BP_{ND} images were normalized to the MNI space using the T1-weighted MR images, and smoothed with a Gaussian kernel of 8 mm FWHM. Anatomic regions of interest were generated in the ventral striatum, dorsal caudate nucleus, and putamen using the AAL (Tzourio-Mazoyer et al., 2002) and Anatomy (Eickhoff et al., 2005) toolboxes. Statistical analysis was performed as described earlier (Tuominen et al., 2015). In the ROI analysis, Pearson correlation was calculated between the tracer-wise BP_{ND} s in the striatal regions of interest. Fisher's z-test was used for quantifying whether ROI-level Pearson correlations between the [¹¹C]raclopride and [¹¹C]carfentanil BP_{ND} values were statistically different between groups.

Results

MOR and D₂R availabilities were associated in the ventral striatum ($r = .62$, $p < 0.05$) and dorsal caudate ($r = .61$, $p < 0.05$) in the control subjects (Figure 1). Preoperatively, the obese subjects had disrupted association

in the ventral striatum ($r = .12$, ns), but unaltered association in dorsal caudate ($r = .43$, $p < 0.05$) (Figure 1). MOR and D₂R availabilities in putamen were not associated in either group.

The association between MOR and D₂R availabilities in the ventral striatum was recovered ($r = .62$, $p < 0.05$) among obese subjects following the surgery-induced weight loss (mean total weight loss 25.0 ± 8.2 kg and 22.1 ± 6.1 %) (Figure 1 and 2). There was no difference between the two surgical procedures in receptor availabilities or the association between receptors before or after surgery.

Figure 1. Correlations between [¹¹C]raclopride BP_{ND} and [¹¹C]carfentanil BP_{ND} in the ventral striatum, dorsal caudate, and putamen. The association is recovered in the ventral striatum after surgery-induced weight loss. Significant association was found in dorsal caudate in all groups, whereas no association was found in putamen in any group.

Figure 2. Mean correlations between [11C]raclopride BP_{ND} and [11C]carfentanil BP_{ND} in non-obese and obese subjects before and after surgery. Asterisks denote significant between-groups differences.

Discussion

Our main finding was that opioid-dopamine interaction is recovered by bariatric surgery and concomitant weight loss. Dysfunctional opioid-dopamine interaction in the ventral striatum is associated with an obese phenotype and may mediate excessive energy uptake, and we have reported earlier that MOR levels return to normal after weight loss (Karlsson et al., 2016). Behaviorally this is in line with previous studies, showing improved satiety and lowered appetite after bariatric surgery (Morinigo et al., 2006; Karamanakos et al., 2008). We have previously shown that striatal opioid and dopamine systems are coupled in non-obese but not in obese subjects (Tuominen et al., 2015). In the normal-weight subjects the interaction was strongest in the ventral striatum, but also significant in dorsal caudate. Growing evidence indicates that MOR and D_2R are expressed in same striatal neurons (Ambrose et al., 2004; Margolis and Hjelmstad, 2014). The interaction between these receptor systems is likely crucial in regulating appetite, because it breaks down in the striatum in the obese subjects, while association in the dorsal caudate remains intact. This might explain unaltered D_2R

levels in obesity: although obesity-dependent dysfunction in dopaminergic system is shown in numerous animal studies, it may be mediated through MOR-dependent mechanisms without having any effect on the actual number of D₂R proteins. Even if the amount of D₂R protein stays the same in obesity, decoupling of MOR and D₂R in the striatum may cause altered dopaminergic functions.

MORs are co-localized with D₂Rs in striosomes (Herkenham and Pert, 1981). Dopaminergic neurons in the striosomes project directly to ventral tegmental area (VTA) and substantia nigra, whereas neurons projecting to GABAergic neurons are distributed in the matrix compartment (Watabe-Uchida et al., 2012). Pathways projecting from striosomes back to the midbrain exert disinhibitory control over the dopaminergic neurons (Fujiyama et al., 2015), thus having direct influence on the reward functions. These neurons are under direct opioidergic control (Banghart et al., 2015). Accordingly, endogenous opioids disinhibit the neurons projecting from the patches to the midbrain (i.e. disinhibiting the disinhibiting neurons), and in this way increase dopaminergic firing in VTA. The rewarding effects of opioids are dependent on the MORs located in the striosomes (Cui et al., 2014)

Based on the observation that dopamine release caused by opioids in the striatum is dependent on the MORs in the striosomes in mice (Cui et al., 2014), we hypothesize that aberrant opioid function in obese humans might lead to diminished dopamine release caused by eating. When obese subjects lose weight, the interaction between MOR and D₂R is reverted. This further supports the notion that the interaction between these receptor systems is a normal state. The dysfunction of opioid-dopamine interaction in the ventral striatum might be an important factor underlying overeating, and thus a feasible target for pharmacological and behavioural interventions. This has already been noted in pharmacological studies. MOR antagonist naltrexone therapy alone does not lead to significant weight loss, but promising results are obtained when it is coupled with bupropion (a dopamine and norepinephrine re-uptake inhibitor) (Lee and Fujioka, 2009; Greenway et al., 2010; Smith et al., 2013; Billes et al., 2014). Combination therapy of naltrexone and

bupropion has been approved by FDA and EMA for weight management in adults (Sherman et al., 2016) and certain amount of obese patients achieve significant weight loss (Fujioka et al., 2016; Mullally et al., 2020; Onakpoya et al., 2020). The favourable effect of the combination therapy may be due to tight coupling of MOR and D₂R. Moreover, the better efficacy of the combination therapy over monotherapies underlines the complex pattern of neurotransmitter networks underlying overeating, and suggests that both aspects of reward functions – *wanting* and *liking*, processes mediated by dopaminergic and opioidergic systems, respectively (Berridge and Kringelbach, 2015) – have to be taken care of in order to treat obese patients.

Limitations of the study

Only female subjects were studied, and the results may not be generalizable to male subjects. It was not possible to differentiate the combined effects of postoperative weight loss and altered gut anatomy and function. Altered neuroreceptor interaction may be due to the changes in gut hormones but also due to reduced intake of palatable foods. Further studies are needed to elucidate the sole effect of weight loss due to altered energy intake on interaction of opioid and dopamine receptors by comparing the effects of weight loss by surgery versus dieting.

Conclusions

Obesity is associated with disrupted opioid-dopamine interaction in the ventral striatum, but this is recovered by weight loss after bariatric surgery. The dysfunction of opioid-dopamine interaction might be an important factor underlying overeating.

References

- Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, Gutierrez JM, Frogley SJ, Ibele AR, Brinton EA, Hopkins PN, McKinlay R, Simper SC, Hunt SC (2017) Weight and Metabolic Outcomes 12 Years after Gastric Bypass. *The New England journal of medicine* 377:1143-1155.
- Ambrose LM, Unterwald EM, Van Bockstaele EJ (2004) Ultrastructural evidence for co-localization of dopamine D2 and micro-opioid receptors in the rat dorsolateral striatum. *The anatomical record Part A, Discoveries in molecular, cellular, and evolutionary biology* 279:583-591.
- Banghart MR, Neufeld SQ, Wong NC, Sabatini BL (2015) Enkephalin Disinhibits Mu Opioid Receptor-Rich Striatal Patches via Delta Opioid Receptors. *Neuron* 88:1227-1239.
- Berridge KC, Kringelbach ML (2015) Pleasure Systems in the Brain. *Neuron* 86:646-664.
- Billes SK, Sinnayah P, Cowley MA (2014) Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss. *Pharmacological research : the official journal of the Italian Pharmacological Society* 84c:1-11.
- Bryant EJ, Malik MS, Whitford-Bartle T, Waters GM (2020) The effects of bariatric surgery on psychological aspects of eating behaviour and food intake in humans. *Appetite* 150:104575.
- Burghardt PR, Rothberg AE, Dykhuis KE, Burant CF, Zubieta JK (2015) Endogenous Opioid Mechanisms Are Implicated in Obesity and Weight Loss in Humans. *J Clin Endocrinol Metab* 100:3193-3201.
- Cambridge VC, Ziauddeen H, Nathan PJ, Subramaniam N, Dodds C, Chamberlain SR, Koch A, Maltby K, Skeggs AL, Napolitano A, Farooqi IS, Bullmore ET, Fletcher PC (2013) Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people. *Biological psychiatry* 73:887-894.
- Chartoff EH, Connery HS (2014) It's MORE exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system. *Frontiers in pharmacology* 5:116.
- Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D, Erritzoe D, Tziortzi AC, Reed LJ, Lingford-Hughes AR, Waldman AD, Schruers KR, Matthews PM, Gunn RN, Nutt DJ, Rabiner EA (2012) Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. *Biological psychiatry* 72:371-377.
- Cui Y, Ostlund SB, James AS, Park CS, Ge W, Roberts KW, Mittal N, Murphy NP, Cepeda C, Kieffer BL, Levine MS, Jentsch JD, Walwyn WM, Sun YE, Evans CJ, Maidment NT, Yang XW (2014) Targeted expression of mu-opioid receptors in a subset of striatal direct-pathway neurons restores opiate reward. *Nature neuroscience* 17:254-261.
- Dang LC, Samanez-Larkin GR, Castellon JJ, Perkins SF, Cowan RL, Zald DH (2016) Associations between dopamine D2 receptor availability and BMI depend on age. *NeuroImage* 138:176-183.
- de Weijer BA, van de Giessen E, Janssen I, Berends FJ, van de Laar A, Ackermans MT, Fliers E, la Fleur SE, Booij J, Serlie MJ (2014) Striatal dopamine receptor binding in morbidly obese women before and after gastric bypass surgery and its relationship with insulin sensitivity. *Diabetologia* 57:1078-1080.
- Dunn JP, Cowan RL, Volkow ND, Feurer ID, Li R, Williams DB, Kessler RM, Abumrad NN (2010) Decreased dopamine type 2 receptor availability after bariatric surgery: preliminary findings. *Brain research* 1350:123-130.
- Eickhoff SB, Stephan KE, Mohlberg H, Grefkes C, Fink GR, Amunts K, Zilles K (2005) A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. *NeuroImage* 25:1325-1335.
- Eisenstein SA, Antenor-Dorsey JA, Gredysa DM, Koller JM, Bihun EC, Ranck SA, Arbelaez AM, Klein S, Perlmutter JS, Moerlein SM, Black KJ, Hershey T (2013) A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-[(11)C]methyl)benperidol. *Synapse (New York, NY)* 67:748-756.
- Farde L, Hall H, Ehrin E, Sedvall G (1986) Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. *Science (New York, NY)* 231:258-261.
- Fields HL, Margolis EB (2015) Understanding opioid reward. *Trends in neurosciences* 38:217-225.

- Frost JJ, Wagner HN, Jr., Dannals RF, Ravert HT, Links JM, Wilson AA, Burns HD, Wong DF, McPherson RW, Rosenbaum AE, et al. (1985) Imaging opiate receptors in the human brain by positron tomography. *Journal of computer assisted tomography* 9:231-236.
- Fujioka K, Plodkowski R, O'Neil PM, Gilder K, Walsh B, Greenway FL (2016) The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. *International journal of obesity* (2005) 40:1369-1375.
- Fujiyama F, Takahashi S, Karube F (2015) Morphological elucidation of basal ganglia circuits contributing reward prediction. *Frontiers in neuroscience* 9:6.
- Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E, Group C-IS (2010) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 376:595-605.
- Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. *NeuroImage* 6:279-287.
- Herkenham M, Pert CB (1981) Mosaic distribution of opiate receptors, parafascicular projections and acetylcholinesterase in rat striatum. *Nature* 291:415-418.
- Horstmann A, Fenske WK, Hankir MK (2015) Argument for a non-linear relationship between severity of human obesity and dopaminergic tone. *Obesity reviews : an official journal of the International Association for the Study of Obesity* 16:821-830.
- Jalabert M, Bourdy R, Courtin J, Veinante P, Manzoni OJ, Barrot M, Georges F (2011) Neuronal circuits underlying acute morphine action on dopamine neurons. *Proceedings of the National Academy of Sciences of the United States of America* 108:16446-16450.
- Kalivas PW (1993) Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. *Brain research Brain research reviews* 18:75-113.
- Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK (2008) Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. *Annals of surgery* 247:401-407.
- Karlsson HK, Tuominen L, Tuulari JJ, Hirvonen J, Parkkola R, Helin S, Salminen P, Nuutila P, Nummenmaa L (2015) Obesity is associated with decreased μ -opioid but unaltered dopamine D2 receptor availability in the brain. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 35:3959-3965.
- Karlsson HK, Tuulari JJ, Tuominen L, Hirvonen J, Honka H, Parkkola R, Helin S, Salminen P, Nuutila P, Nummenmaa L (2016) Weight loss after bariatric surgery normalizes brain opioid receptors in morbid obesity. *Molecular psychiatry* 21:1057-1062.
- Le Merrer J, Becker JA, Befort K, Kieffer BL (2009) Reward processing by the opioid system in the brain. *Physiological reviews* 89:1379-1412.
- Lee MW, Fujioka K (2009) Naltrexone for the treatment of obesity: review and update. *Expert opinion on pharmacotherapy* 10:1841-1845.
- Lee Y, Kroemer NB, Oehme L, Beuthien-Baumann B, Goschke T, Smolka MN (2018) Lower dopamine tone in the striatum is associated with higher body mass index. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 28:719-731.
- Margolis EB, Hjelmstad GO (2014) Direct bidirectional mu-opioid control of midbrain dopamine neurons. *Neuron* 82:14707-14716.
- Mick I, Myers J, Stokes PR, Erritzoe D, Colasanti A, Bowden-Jones H, Clark L, Gunn RN, Rabiner EA, Searle GE, Waldman AD, Parkin MC, Brailsford AD, Nutt DJ, Lingford-Hughes AR (2014) Amphetamine induced endogenous opioid release in the human brain detected with [(1)(1)C]carfentanil PET: replication in an independent cohort. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)* 17:2069-2074.
- Morales I, Berridge KC (2020) 'Liking' and 'wanting' in eating and food reward: Brain mechanisms and clinical implications. *Physiology & behavior* 227:113152.

- Morinigo R, Moize V, Musri M, Lacy AM, Navarro S, Marin JL, Delgado S, Casamitjana R, Vidal J (2006) Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. *The Journal of clinical endocrinology and metabolism* 91:1735-1740.
- Mullally JA, Chung WK, LeDuc CA, Reid TJ, Febres G, Holleran S, Ramakrishnan R, Korner J (2020) Weight Loss Response to Naltrexone/Bupropion is Modulated by the Taq1A Genetic Variant near DRD2 (rs1800497): A Pilot Study. *Diabetes, obesity & metabolism*.
- Nathan PJ, O'Neill BV, Bush MA, Koch A, Tao WX, Maltby K, Napolitano A, Brooke AC, Skeggs AL, Herman CS, Larkin AL, Ignar DM, Richards DB, Williams PM, Bullmore ET (2012) Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel mu-opioid receptor inverse agonist. *Journal of clinical pharmacology* 52:464-474.
- Onakpoya IJ, Lee JJ, Mahtani KR, Aronson JK, Heneghan CJ (2020) Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. *British journal of clinical pharmacology* 86:646-667.
- Pecina S, Smith KS (2010) Hedonic and motivational roles of opioids in food reward: implications for overeating disorders. *Pharmacology, biochemistry, and behavior* 97:34-46.
- Rada P, Barson JR, Leibowitz SF, Hoebel BG (2010) Opioids in the hypothalamus control dopamine and acetylcholine levels in the nucleus accumbens. *Brain research* 1312:1-9.
- Salamone JD, Correa M (2013) Dopamine and food addiction: lexicon badly needed. *Biological psychiatry* 73:e15-24.
- Sherman MM, Ungureanu S, Rey JA (2016) Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults. *P & T : a peer-reviewed journal for formulary management* 41:164-172.
- Smith SR, Fujioka K, Gupta AK, Billes SK, Burns C, Kim D, Dunayevich E, Greenway FL (2013) Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. *Diabetes, obesity & metabolism* 15:863-866.
- Soderman AR, Unterwald EM (2009) Cocaine-induced mu opioid receptor occupancy within the striatum is mediated by dopamine D2 receptors. *Brain research* 1296:63-71.
- Spanagel R, Herz A, Shippenberg TS (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. *Proceedings of the National Academy of Sciences of the United States of America* 89:2046-2050.
- Steele KE, Prokopowicz GP, Schweitzer MA, Magunsuon TH, Lidor AO, Kuwabawa H, Kumar A, Brasic J, Wong DF (2010) Alterations of central dopamine receptors before and after gastric bypass surgery. *Obesity surgery* 20:369-374.
- Stice E, Burger K (2019) Neural vulnerability factors for obesity. *Clinical psychology review* 68:38-53.
- Stice E, Yokum S, Burger KS, Epstein LH, Small DM (2011) Youth at risk for obesity show greater activation of striatal and somatosensory regions to food. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 31:4360-4366.
- Taber MT, Zernig G, Fibiger HC (1998) Opioid receptor modulation of feeding-evoked dopamine release in the rat nucleus accumbens. *Brain research* 785:24-30.
- Tuominen L, Tuulari J, Karlsson H, Hirvonen J, Helin S, Salminen P, Parkkola R, Hietala J, Nuutila P, Nummenmaa L (2015) Aberrant mesolimbic dopamine-opiate interaction in obesity. *NeuroImage* 122:80-86.
- Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *NeuroImage* 15:273-289.
- Volkow ND, Wise RA (2005) How can drug addiction help us understand obesity? *Nature neuroscience* 8:555-560.

- Volkow ND, Wang GJ, Telang F, Fowler JS, Thanos PK, Logan J, Alexoff D, Ding YS, Wong C, Ma Y, Pradhan K (2008) Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors. *NeuroImage* 42:1537-1543.
- Watabe-Uchida M, Zhu L, Ogawa SK, Vamanrao A, Uchida N (2012) Whole-brain mapping of direct inputs to midbrain dopamine neurons. *Neuron* 74:858-873.
- Yeomans MR, Gray RW (2002) Opioid peptides and the control of human ingestive behaviour. *Neuroscience and biobehavioral reviews* 26:713-728.